Item 2.02 Results of Operations and Financial Condition
Although it has not finalized its full financial results for the fourth quarter
and fiscal year ended December 31, 2020, the Company will announce during the
39th Annual J.P. Morgan Healthcare Conference, which begins on January 11, 2021,
that it expects to report that it had approximately $210 million in cash, cash
equivalents and available for sale securities as of December 31, 2020.
The information contained in this Item 2.02 of Form 8-K is unaudited and
preliminary, and does not present all information necessary for an understanding
of the Company's financial condition as of December 31, 2020 and its results of
operations for the three months and year ended December 31, 2020. The audit of
the Company's financial statements for the year ended December 31, 2020 is
ongoing and could result in changes to the information set forth above. The
Company anticipates making a public announcement of its results of operations
for the fourth quarter and fiscal year ended December 31, 2020 on or about
February 25, 2021.
Item 8.01 Other Events
2020 Year End Cash, Cash Equivalents and Available for Sale Securities
The information in Item 2.02 of this Form 8-K is incorporated by reference.
GATHER2 Trial Enrollment Update
The Company expects to complete patient enrollment for GATHER2, its
international, randomized, double-masked, sham controlled, multi-center Phase 3
clinical trial assessing the safety and efficacy of Zimura® for the treatment of
geographic atrophy secondary to age-related macular degeneration, during the
second half of 2021. The Company plans to provide additional updates on patient
enrollment for this clinical trial as the year progresses.
2
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
IVERIC BIO, INC. 
